USA flag logo/image

An Official Website of the United States Government

EXPRESSION OF P FALCIPARUM LSA-1 SUBUNITS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
54174
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43AI047506-01A1
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
HAWAII BIOTECH, INC.
99-193 AIEA HEIGHTS DRIVE, SUITE 200 AIEA, HI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: EXPRESSION OF P FALCIPARUM LSA-1 SUBUNITS
Agency: HHS
Contract: N/A
Award Amount: $175,002.00
 

Abstract:

DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a tropical parasitic disease that is a significant health threat. Each year, approximately 500 million people become infected and 2 to 3 million die worldwide. There is a great need to control the spread of this disease. Recently, the development of malaria vaccines has focused on the use of recombinant DNA technology. The inclusion of pre-erythrocytic antigens, such as the liver stage antigen-1 (LSA-1), is important in the development of a successful multi-component malaria vaccine. To date, most efforts to develop LSA-1-based vaccines have focused on the use of defined peptide sequences. Phase I research will test the feasibility of efficiently expressing truncated forms of the Plasmodium falciparum LSA-1 antigen. These recombinant subunits have the potential to provide a broader immune response than the synthetic peptides tested. The expression system proposed for this research has been shown to express high levels of recombinant proteins, including a malaria erythrocyte stage vaccine candidate antigen. The successful expression of high levels of a liver stage candidate vaccine antigen with appropriate antigenic and immunogenic characteristics could contribute to the development of a safe, efficacious and cost effective vaccine for malaria. PROPOSED COMMERCIAL APPLICATION: Malaria poses a significant health threat. Annually, approximately 500 million people become infected and 1 to 2 million die. Currently, there is no vaccine for malaria. The proposed research will test the feasibility of expressing and secreting a malaria subunit targeted for vaccine development. Successful expression of high levels of this subunit could contribute to the development of a safe, efficacious and cost effective malaria vaccine.

Principal Investigator:

David E. Clements

Business Contact:


8084865333
JRHODEN@HIBIOTECH.COM
Small Business Information at Submission:

HAWAII BIOTECHNOLOGY GROUP, INC.
99-193 AIEA HEIGHTS DR, STE 236 AIEA, HI 96701

EIN/Tax ID: 990214983
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No